Home Cart Sign in  
Chemical Structure| 380843-75-4 Chemical Structure| 380843-75-4

Structure of Bosutinib
CAS No.: 380843-75-4

Chemical Structure| 380843-75-4

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

Bosutinib is an inhibitor of Src and Abl with IC50 of 1.2 nM and 1 nM.

Synonyms: SKI-606

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

US Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Product Citations

Leclercq, Gabrielle ;

Abstract: T cell bispecific antibodies (TCBs) are a novel class of T cell engagers redirecting T cells towards tumor cells, facilitating the formation of a cytotoxic synapse and resulting in tumor celllysis. On-target activity of TCBs may come with a risk of Cytokine Release Syndrome (CRS), characterized by elevated levels of pro-inflammatory cytokines in the serum, such as IL-6, IL-1β, TNF-α or IFN-γ and over activation of immune cells. Besides, the expression of the tumorassociated antigen on healthy cells may induce off-tumor activity of the TCB and contribute to inflammation. Despite the use of step-up dosing, glucocorticoids, or tocilizumab to manage or prevent these safety liabilities, they remain the major dose-limiting toxicities associated with the treatment of T cell engagers, highlighting the need to develop preventive mitigation treatments. To this aim, we investigated the biological mechanisms and the chronology of events involved in TCB-mediated cytokine release and explored mitigation strategies that might retain profound treatment efficacy while reducing cytokine release. Using an in vitro co-culture of peripheral blood mononuclear cells (PBMCs) or total leukocytes(PBMCs + neutrophils) and target cells with the respective TCBs, or whole blood treated with a B cell depleting TCB, we confirmed the contribution of T cell and myeloid cells and revealed the role of neutrophils in the TCB-mediated cytokine release. In the same model, the use of anticytokine neutralizing antibodies provided insights into the chronology of events triggering the cascade of cytokines after TCB stimulation. Ultimately this work guided the evaluation of mitigation strategies directed against T-cell derived cytokine release by targeting kinases involved in signaling pathways downstream of the T cell receptor (TCR) after stimulation with TCBs. A novel small molecule-kinase inhibitors screen identified mTOR, JAK and Src inhibitors as candidates to switch-off T-cell derived cytokine release. We validated the effects of these kinase inhibitors and fine-tuned their effective doses in in vitro co-cultures of peripheral blood mononuclear cells (PBMCs) and tumor cells with the respective TCBs. In vivo, we used nontumor or tumor-bearing-humanized NSG mice to assess the effect of mTOR, JAK and Srcinhibitors on CD19-TCB-mediated cytokine release and anti-tumor efficacy. Altogether, we confirmed the biological mechanisms of the TCB-mediated cytokine cascade and revealed the contribution of neutrophils. Our work on kinase inhibitors highlights their differential activities on the inhibition of cytokine release and/or T cell cytotoxicity and demonstrates the decoupling between both mechanisms. Our data open new horizons for the prophylactic mitigation of CRS with the use of FDA approved mTOR and JAK inhibitors or the transient use of the Src inhibitor dasatinib. Finally, our results also indicate that dasatinib may serve as an “antidote” against adverse events related to the treatment with TCBs such as high grade CRS or unpredictable off-tumor activity of TCBs, a strategy which is now implemented the clinic.

Purchased from AmBeed: ; ; ; ;

Alternative Products

Product Details of Bosutinib

CAS No. :380843-75-4
Formula : C26H29Cl2N5O3
M.W : 530.45
SMILES Code : N#CC1=C(NC2=CC(OC)=C(Cl)C=C2Cl)C3=CC(OC)=C(OCCCN4CCN(C)CC4)C=C3N=C1
Synonyms :
SKI-606
MDL No. :MFCD07367846
InChI Key :UBPYILGKFZZVDX-UHFFFAOYSA-N
Pubchem ID :5328940

Safety of Bosutinib

GHS Pictogram:
Signal Word:Warning
Hazard Statements:H319-H413
Precautionary Statements:P305+P351+P338

Related Pathways of Bosutinib

RTK

Isoform Comparison

Biological Activity

Target
  • Src

    Src, IC50:1.2 nM

In Vitro:

Cell Line
Concentration Treated Time Description References
BEAS-2B cells 5 or 10 μM 30 min To investigate the inhibitory effect of Bosutinib on Src kinase activity, it was found that pretreatment with Bosutinib significantly inhibited O3-induced EGFR phosphorylation. PMC4348738
ParC5 cells 0.1–1.0 μM 30 min Bosutinib inhibited IR-induced apoptosis in ParC5 cells and suppressed phosphorylation of PKC δ at Y64 and Y155. PMC5587414
KRAS mutant non-small cell lung cancer cells 0.1, 0.5, 1 μM Bosutinib inhibited migration and invasion in KRAS mutant cells but had no significant effect on KRAS wild-type cells. PMC3930897
NCI-H1792 cells 0.5, 1 μM Bosutinib-induced inhibition of cell migration and invasion was dependent on ACK1, not SRC. PMC3930897
Human umbilical vein endothelial cells 0.5 μM 3 h To investigate the effect of Bosutinib on human umbilical vein endothelial cells, results showed that Bosutinib treatment did not affect the phosphorylation of eNOS. PMC8516812
K562DOX cells 1 μM 1 h To evaluate the role of ABCB1 in bosutinib transport, results showed the lowest intracellular level of bosutinib in K562DOX cells PMC4491863
K562S cells 1 μM 1 h To evaluate bosutinib transport in normal cells, results showed high intracellular levels of bosutinib in K562S cells PMC4491863
Human umbilical vein endothelial cells 0.5 μM 3 h To investigate the effect of Bosutinib on eNOS phosphorylation in endothelial cells, results showed that Bosutinib treatment did not affect eNOS phosphorylation. PMC8516812

In Vivo:

Species
Animal Model
Administration Dosage Frequency Description References
Mice KRT5Cre/tdTomatoLoxP transgenic mice Tail vein injection 30 mg/kg Single injection, observed for 3 hours To study the effect of SKI606 on the retraction of basal cell axiopodia, results showed that SKI606 induced the retraction of axiopodia. PMC4754344
Mice Endothelial cell-specific c-Abl knockout mice Oral 100 mg/kg Once daily for 4 to 7 days To investigate the effect of Bosutinib on blood pressure, results showed that Bosutinib treatment increased blood pressure in mice, and this effect was independent of endothelial c-Abl. PMC8516812
Nude mice K562S, K562DOX, and K562DOX/sh P-GP xenograft model Oral 150 mg/kg Once daily, 5 days/week for 2 weeks To evaluate the effect of ABCB1 overexpression on the anti-tumor activity of bosutinib, results showed that K562DOX mice had a limited response to bosutinib treatment and relapsed, while K562DOX/sh P-GP mice were fully sensitive to treatment PMC4491863
Mice Endothelial cell-specific c-Abl knockout mice Oral gavage 100 mg/kg Once daily for 4 to 7 days To investigate the effect of Bosutinib on blood pressure and its mechanism, results showed that Bosutinib increased blood pressure by upregulating soluble epoxide hydrolase (sEH), and the sEH inhibitor TPPU reversed this effect. PMC8516812

Clinical Trial:

NCT Number Conditions Phases Recruitment Completion Date Locations
NCT02551718 Acute Leukemia of Ambiguous Li... More >>neage Recurrent Adult Acute Lymphoblastic Leukemia Recurrent Adult Acute Myeloid Leukemia Recurrent Childhood Acute Lymphoblastic Leukemia Recurrent Childhood Acute Myeloid Leukemia Refractory Acute Myeloid Leukemia Refractory Adult Acute Lymphoblastic Leukemia Refractory Childhood Acute Lymphoblastic Leukemia Less << Not Applicable Recruiting - United States, Washington ... More >> Fred Hutch/University of Washington Cancer Consortium Recruiting Seattle, Washington, United States, 98109 Contact: Pamela S. Becker    206-616-1589    pbecker@u.washington.edu    Principal Investigator: Pamela S. Becker Less <<
NCT03610971 Chronic Phase Chronic Myeloid ... More >>Leukemia Chronic Myeloid Leukemia, Chronic Phase Less << Phase 2 Not yet recruiting January 2022 United States, Florida ... More >> H. Lee Moffitt Cancer Center and Research Institute Not yet recruiting Tampa, Florida, United States, 33612 Contact: Anthony McLaughlin    813-745-5941    anthony.mclaughlin@moffitt.org    Contact: Kendra Sweet, M.D.    813-745-8986    kendra.sweet@moffitt.org    Principal Investigator: Kendra Sweet, M.D. Less <<
NCT03746054 Chronic Myeloid Leukemia (CML) Phase 3 Not yet recruiting March 2023 -
NCT02269267 Leukemia, Myeloid, Chronic Phase 2 Active, not recruiting December 2021 United States, California ... More >> Helen Diller Family Comprehensive Cancer Center University of California San Francisco, California, United States, 94143 United States, Florida Moffit Cancer Center Tampa, Florida, United States, 33612 United States, Georgia Winship Cancer Institute of Emory University Atlanta, Georgia, United States, 30322 United States, Illinois The University of Chicago Chicago, Illinois, United States, 60637 The University of Chicago Medicine Comprehensive Cancer Center at Silver Cross New Lenox, Illinois, United States, 60451 United States, Massachusetts Beth Israel Deaconess Medical Center (Satellite site of Dana Farber) Boston, Massachusetts, United States, 02215 Dana Farber Cancer Institute Boston, Massachusetts, United States, 02215 United States, Michigan Karmanos Cancer Institute of Wayne State University Detroit, Michigan, United States, 48201 United States, New York Roswell Park Cancer Institute Buffalo, New York, United States, 14263 Weill Medical College of Cornell University New York, New York, United States, 10021 Memorial Sloan Kettering Cancer Center New York, New York, United States, 10065 United States, North Carolina Duke University Medical Center Durham, North Carolina, United States, 27710 United States, Texas MD Anderson Cancer Center Houston, Texas, United States, 77054 United States, Utah University of Utah Huntsman Cancer Institute Salt Lake City, Utah, United States, 84132-2408 United States, Washington Fred Hutchinson Cancer Research Center Seattle, Washington, United States, 98109-1024 United States, Wisconsin Froedtert Hospital & Medical College of Wisconsin Milwaukee, Wisconsin, United States, 53226 Less <<
NCT02767063 Leukemia, Myeloid, Chronic-Pha... More >>se Less << Phase 1 Phase 2 Recruiting June 2021 France ... More >> Martine GARDEMBAS Recruiting Angers, France Contact: Martine GARDEMBAS    02.41.35.44.75    MaGardembas@chu-angers.fr    Pascale CONY.MAKHOUL Recruiting Annecy, France Contact: Pascale CONY.MAKHOUL    04.50.63.64.31    pconymakhoul@ch-annecygenevois.fr    Thorsten BRAUN Recruiting Bobigny, France Contact: Thorsten BRAUN    01.48.95.54.58    Thorsten.braun@avc.aphp.fr    Etienne Recruiting Bordeaux, France Contact: Gabriel Etienne    05.56.33.04.76    G.Etienne@bordeaux.unicancer.fr    CHU Côte de Nacre Not yet recruiting Caen, France Contact: Hyacynthe Johnson-Ansah    02.31.27.25.39    Johnsonansah-a@chu-caen.fr    CHU Estaing Not yet recruiting Clermont-Ferrand, France Contact: Marc BERGER       mberger@chu-clermontferrand.fr    CH Henri Mondor Recruiting Créteil, France Contact: ROY Lydia          Rousselot Recruiting Le Chesnay, France Contact: Philippe Rousselot    01.39.63.89.09    phrousselot@ch-versailles.fr    CHU Lille Recruiting Lille, France Contact: COITEUX Valérie          CHU de LIMOGES Not yet recruiting Limoges, France Contact: Amélie PENOT    05.55.05.66.42    Amelie.penot@chu-limoges.fr    Franck NICOLINI Recruiting Lyon, France Contact: Franck NICOLINI    04.72.11.74.01    franck.nicolini@chu-lyon.fr    Institut P Calmette Recruiting Marseille, France Contact: CHARBONNIER Aude          Viviane DUBRUILLE Recruiting Nantes, France Contact: Viviane DUBRUILLE    02.40.08.32.71    Viviane.dubruille@chu-nantes.fr    Hopital l'Archet Not yet recruiting Nice, France Contact: Laurence LEGROS    04.92.03.58.41    legros.l@chu-nice.fr    Eric JOURDAN Recruiting Nimes, France Contact: Eric JOURDAN    04.66.68.32.31    eric.jourdan@chu-nimes.fr    Hôpital La Source Recruiting Orléans, France Contact: BENBRAHIM Omar          Delphine REA _St louis Recruiting Paris, France Contact: Delphine REA    01.42.49.96.49    delphine.rea@aphp.fr    Simona LAPUSAN_St Antoine Recruiting Paris, France Contact: Simona LAPUSAN    01.49.28.34.42    Simona.lapusan@sat.aphp.fr    Cayssials Recruiting Poitiers, France Contact: Emilie Cayssials    : 05.49.44. 44.72    e.cayssials@chu-poitiers.fr    CHU de Rennes - Pontchaillou Recruiting Rennes, France Contact: ESCOFFRE-BARBE Martine          Hôpital René Huguenin Not yet recruiting Saint-Cloud, France Contact: Sylvie GLAISNER    01.47.11.15.30    Sylvie.glaisner@curie.net    Institut Universitaire contre le Cancer Not yet recruiting Toulouse, France Contact: Françoise HUGUET    05.31.15.63.56    Huguet.françoise@iuct-oncopole.fr    CHU Tours Not yet recruiting Tours, France Contact: DARTIGEAS Caroline Less <<
NCT00406406 Healthy PHASE1 COMPLETED 2025-08-07 Utrecht, 3584 CJ, Netherlands
NCT00499538 Healthy PHASE1 COMPLETED 2025-09-07 San Antonio, Texas, 78217, Uni... More >>ted States Less <<
NCT00434486 Healthy PHASE1 COMPLETED 2025-03-07 Philadelphia, Pennsylvania, 19... More >>148, United States Less <<
NCT02693535 Lymphoma, Non-Hodgkin ... More >> Multiple Myeloma Advanced Solid Tumors Less << Phase 2 Recruiting - -
NCT01001936 Tumors PHASE1 COMPLETED 2025-12-08 -
NCT02921477 Mild Cognitive Impairment ... More >> Dementia Less << Phase 1 Unknown September 2018 United States, California ... More >> Neurological Associates of West LA Santa Monica, California, United States, 90403 Less <<
NCT02638467 Leukemia Myel... More >>ogenous Chronic BCR-ABL Positive Less << Phase 2 Recruiting January 2019 Italy ... More >> ASST-Monza Recruiting Monza, Italy/MB, Italy, 20900 Contact: Carlo Gambacorti-Passerini, MD    +390392339553    carlo.gambacorti@unimib.it    Principal Investigator: Carlo Gambacorti-Passerini, MD          Ospedale San Raffaele Recruiting Milano, MI, Italy, 20132 Contact: Fabio Ciceri, MD    +390226437703    fabio.ciceri@hsr.it Less <<
NCT00757341 Healthy Subjects PHASE1 COMPLETED 2025-12-08 Tacoma, Washington, 98418, Uni... More >>ted States Less <<
NCT00777530 Breast Cancer ... More >> Tumors Leukemia Less << Phase 1 Completed - Netherlands ... More >> Utrecht, Netherlands, 3584 Less <<
NCT00195260 Neoplasms Phase 1 Completed - United States, Alabama ... More >> Pfizer Investigational Site Birmington, Alabama, United States, 35233 United States, Arizona Pfizer Investigational Site Scottsdale, Arizona, United States, 85258 United States, California Pfizer Investigational Site Los Angeles, California, United States, 90033 United States, Florida Pfizer Investigational Site Tampa, Florida, United States, 33612 United States, Georgia Pfizer Investigational Site Atlanta, Georgia, United States, 30341 United States, Indiana Pfizer Investigational Site Indianpolis, Indiana, United States, 46202 United States, Maryland Pfizer Investigational Site Baltimore, Maryland, United States, 21287 United States, Michigan Pfizer Investigational Site Detroit, Michigan, United States, 48202 Pfizer Investigational Site Lansing, Michigan, United States, 48910 United States, New York Pfizer Investigational Site New York, New York, United States, 10016 Pfizer Investigational Site New York, New York, United States, 10032 United States, North Carolina Pfizer Investigational Site Charlotte, North Carolina, United States, 28203 Pfizer Investigational Site Charlotte, North Carolina, United States, 28211 Pfizer Investigational Site UNC Chapel Hill, North Carolina, United States, 27514 Pfizer Investigational Site UNC Chapel Hill, North Carolina, United States, 27759 United States, Ohio Pfizer Investigational Site Cleveland, Ohio, United States, 44106-1736 United States, Texas Pfizer Investigational Site San Antonio, Texas, United States, 78258 Pfizer Investigational Site Tyler, Texas, United States, 75702 United States, Washington Pfizer Investigational Site Seattle, Washington, United States, 98104 Less <<
NCT00319254 Breast Neoplasms ... More >> Neoplasm Metastasis Less << Phase 2 Completed - United States, California ... More >> Pfizer Investigational Site Duarte, California, United States, 91010-3000 Pfizer Investigational Site Santa Monica, California, United States, 90404 United States, Florida Pfizer Investigational Site Tampa, Florida, United States, 33612 United States, Ohio Pfizer Investigational Site Cleveland, Ohio, United States, 44195 Australia, New South Wales Pfizer Investigational Site Darlinghurst, New South Wales, Australia, 2010 France Pfizer Investigational Site Dijon, France, 21034 Pfizer Investigational Site Saint-Herblain, France, 44805 Hong Kong Pfizer Investigational Site Pokfulam, Hong Kong Malta Pfizer Investigational Site Floriana, Malta, VLT 14 Poland Pfizer Investigational Site Lodz, Poland, 90-553 Pfizer Investigational Site Wroclaw, Poland, 51-124 Russian Federation Pfizer Investigational Site Moscow, Russian Federation, 115478 Ukraine Pfizer Investigational Site Dnipropetrovsk, Ukraine, 49102 Pfizer Investigational Site Sumy, Ukraine, 40005 Pfizer Investigational Site Uzhgorod, Ukraine, 88014 Less <<
NCT00880009 Breast Cancer Phase 2 Terminated(See termination rea... More >>son in detailed description.) Less << - United States, California ... More >> Pfizer Investigational Site Whittier, California, United States, 90603 United States, Illinois Pfizer Investigational Site Joliet, Illinois, United States, 60435 Pfizer Investigational Site Niles, Illinois, United States, 60714 United States, Massachusetts Pfizer Investigational Site Boston, Massachusetts, United States, 02114 United States, Michigan Pfizer Investigational Site Detroit, Michigan, United States, 84202 Belgium Pfizer Investigational Site Wilrijk, Belgium, 2610 China, Beijing Pfizer Investigational Site Beijing, Beijing, China, 100021 Hong Kong Pfizer Investigational Site Hong Kong, Hong Kong Hungary Pfizer Investigational Site Budapest, Hungary, 1122 Poland Pfizer Investigational Site Warszawa, Poland, 04125 Singapore Pfizer Investigational Site Singapore, Singapore, 308433 Less <<
NCT00880009 - Terminated(See termination rea... More >>son in detailed description.) Less << - -
NCT00759837 Breast Cancer|Leukemia, Myeloi... More >>d, Chronic Less << PHASE1 COMPLETED 2025-05-09 Warsaw, 02-507, Poland
NCT00914121 Healthy Subjects Phase 1 Completed - United States, Washington ... More >> Tacoma, Washington, United States, 98418 Less <<
NCT03297606 Lymphoma, Non-Hodgkin ... More >> Multiple Myeloma Advanced Solid Tumors Less << Phase 2 Recruiting September 2021 Canada, British Columbia ... More >> BCCA - Vancouver Cancer Centre Recruiting Vancouver, British Columbia, Canada, V5Z 4E6 Contact: Daniel John Renouf    604 877-6000 ext 672357       Canada, Ontario London Regional Cancer Program Recruiting London, Ontario, Canada, N6A 5W9 Contact: Stephen Welch    519 685-8640       Ottawa Hospital Research Institute Recruiting Ottawa, Ontario, Canada, K1H 8L6 Contact: John Hilton    613 737-7700 ext 70179       University Health Network Recruiting Toronto, Ontario, Canada, M5G 2M9 Contact: Lillian Siu    416 946-2911       Canada, Quebec The Jewish General Hospital Recruiting Montreal, Quebec, Canada, H3T 1E2 Contact: Cristiano Ferrario    514 398-8307 Less <<
NCT00319254 - Completed - -
NCT03747679 CML Phase 1 Not yet recruiting December 20, 2018 Belgium ... More >> Pfizer Clinical Research Unit Not yet recruiting Brussels, Belgium, B-1070 Less <<
NCT02228382 Previously Treated PH + CML PHASE4 TERMINATED 2020-10-13 Keck Hospital of USC, Los Ange... More >>les, California, 90033, United States|LAC+USC Medical Center, Los Angeles, California, 90033, United States|USC/Norris Comprehensive Cancer Center, Los Angeles, California, 90033, United States|Sylvester Deerfield Beach, Deerfield Beach, Florida, 33442, United States|University of Miami Hospital & Clinics, Miami, Florida, 33136, United States|Indiana Blood and Marrow Transplantation-Clinic, Indianapolis, Indiana, 46237, United States|Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, Maryland, 21287, United States|Siteman Cancer Center - West County, Creve Coeur, Missouri, 63141-6337, United States|Barnes-Jewish Hospital, Saint Louis, Missouri, 63110, United States|Washington University School of Medicine, Saint Louis, Missouri, 63110, United States|Siteman Cancer Center - South County, Saint Louis, Missouri, 63129, United States|Weill Cornell Medical College - New York-Presbyterian Hospital, New York, New York, 10021, United States|Seattle Cancer Care Alliance, Seattle, Washington, 98109, United States|Medizinische Universitaet Innsbruck, Innsbruck, 6020, Austria|Ordensklinikum Linz Gmbh Barmherzige Schwestern, Linz, 4010, Austria|Institut Bergonie, Bordeaux Cedex 09, 33076, France|Centre Hospitalier de Versailles (CHV)-Hopital Andre Mignot Service d'Hematologie Clinique- Oncology, Le Chesnay Cedex, 78157, France|Centre Regional De Lutte Contre Le Cancer, Marseille, 13009, France|Hopital Archet I, Nice Cedex 3, 06202, France|Institut Universitaire du Cancer Toulouse - Oncopole, Toulouse Cedex 9, 31059, France|CHU Brabois, Vandoeuvre-les-Nancy cedex, 54511, France|RWTH Uniklinik Aachen Klinik fur Onkologie, Hamatologie und Stammzelltransplantation, Aachen, 52074, Germany|Charite - Universitaetsmedizin Berlin - Campus Virchow-Klinikum (CVK), Berlin, 13353, Germany|Universitaetsklinikum Hamburg-Eppendorf, Hamburg, 20246, Germany|Klinik fur Innere Medizin II, Jena, 07747, Germany|Universitaetsklinikum Koeln (AoeR), Koeln, 50937, Germany|III. Medizinische Klinik Universitaetsmedizin Mannheim, Mannheim, D-68167, Germany|AOU Policlinico Consorziale di Bari - UO Ematologia con Trapianto, Bari, BA, 70124, Italy|A.O.U. Policlinico S. Orsola-Malpighi, Bologna, BO, 40138, Italy|Azienda Socio Sanitaria Territoriale - ASST Monza, Monza, MB, 20900, Italy|Ospedale S. Eugenio - UOC Ematologia, Rome, RM, 00144, Italy|AOU San Luigi Gonzaga SCDU Medicina Interna II ad indirizzo Ematologico, Orbassano, TO, 10043, Italy|AOU Policlinico Vittorio Emanuele-P.O.G. Rodolico, Catania, 95123, Italy|SOD Ematologia, Firenze, 50134, Italy|A.O. Ospedale Niguarda Ca Granda - SC Ematologia, Milano, 20162, Italy|Haukeland Universitetssjukehus, Bergen, 5021, Norway|St Olav Hospital, Trondheim, 7030, Norway|Hospital Universitario Quiron Madrid, Pozuelo de Alarcon, Madrid, 28223, Spain|Hospital Universitari Vall d' Hebron, Barcelona, 08035, Spain|Hospital Universitari Vall d'Hebron, Barcelona, 08035, Spain|Hospital Clinic De Barcelona, Barcelona, 08036, Spain|Hospital Universitario de La Princesa, Madrid, 28006, Spain|Hospital Universitario Ramon y Cajal, Madrid, 28034, Spain|Hospital Clinico Universitario de Salamanca, Salamanca, 37007, Spain|Hospital Universitari i Politecnic La Fe de Valencia, Valencia, 46026, Spain|Hospital de dia Quiron Zaragoza, Zaragoza, 50012, Spain|Hematologiskt centrum, Stockholm, 171 76, Sweden|Akademiska Sjukhuset, Uppsala, 751 85, Sweden Less <<
NCT00725426 Healthy PHASE1 COMPLETED 2025-08-08 -
NCT00793546 Advanced Breast Cancer Phase 2 Terminated(See termination rea... More >>son in detailed description.) Less << - -
NCT01233882 Renal Disease, End-Stage ... More >> Renal Insufficiency, Chronic Renal Insufficiency, Acute Less << Phase 1 Completed - United States, Florida ... More >> Pfizer Investigational Site DeLand, Florida, United States, 32720 Pfizer Investigational Site Gainesville, Florida, United States, 32608 Pfizer Investigational Site Miami, Florida, United States, 33169 Pfizer Investigational Site Orlando, Florida, United States, 32806 United States, Minnesota Pfizer Investigational Site Saint Paul, Minnesota, United States, 55114 Less <<
NCT00195260 - Completed - -
NCT00952913 Healthy Phase 1 Completed - United States, Florida ... More >> Pfizer Investigational Site Miami, Florida, United States, 33126 Less <<
NCT00811070 Chronic Myelogenous Leukemia Phase 2 Completed - Japan ... More >> Tohoku University Hospital Sendai-city, Miyagi, Japan, 980-8574 National Cancer Center Hospital Chuo-ku, Tokyo, Japan, 104-0045 Toyohashi Municipal Hospital Aichi, Japan, 441-8570 Japanese Red Cross Nagoya First Hospital Aichi, Japan, 453-8511 Aichi Cancer Center Aichi, Japan, 464-8681 Akita University Hospital Akita, Japan, 010-8543 Chiba University Hospital Chiba, Japan, 260-8677 National Hospital Organization Kyushu Cancer Center Fukuoka, Japan, 811-1395 Harasanshin Hospital Fukuoka, Japan, 812-0033 Kobe City Medical Center General Hospital Hyogo, Japan, 650-0047 Hospital of Hyogo College of Medicine Hyogo, Japan, 663-8501 Kanazawa University Hospital Ishikawa, Japan, 920-8641 Tokai University Hospital Kanagawa, Japan, 259-1193 Kumamoto University Hospital Kumamoto, Japan, 860-8556 University Hospital,Kyoto Prefectural University of Medicine Kyoto, Japan, 602-8566 Okayama University Hospital Okayama, Japan, 700-8558 Osaka University Hospital Osaka, Japan, 565-0871 Kinki University School of Medicine Osaka, Japan, 589-8511 Saga University Hospital Saga, Japan, 846-8501 Hamamatsu Medical Univ. HP Faculty of Medicine Shizuoka, Japan, 431-3192 Tokyo Metropolitan Cancer&Infectious disease Ctr Komagome Hp Tokyo, Japan, 113-8677 Japanese Red Cross Medical Center Tokyo, Japan, 150-8935 Jikei University Hospital Daisan Tokyo, Japan, 201-8601 Less <<
NCT00793546 - Terminated(See termination rea... More >>son in detailed description.) Less << - -
NCT00811070 - Completed - -
NCT00721474 Healthy Subjects Phase 1 Completed - United States, Washington ... More >> Tacoma, Washington, United States, 98418 Less <<
NCT01233869 Polycystic Kidney, Autosomal D... More >>ominant Less << Phase 2 Completed - -
NCT01233869 - Completed - -
NCT00934674 Healthy Phase 1 Completed - United States, Washington ... More >> Tacoma, Washington, United States, 98418 Less <<
NCT00574873 Chronic Myeloid Leukemia Phase 3 Completed - -
NCT00574873 - Completed - -
NCT02501330 Chronic Myelogenous Leukemia COMPLETED 2024-02-28 Shibuya-ku, 151-8589, Japan
NCT02102633 Healthy Phase 1 Completed - United States, Florida ... More >> Pfizer Investigational Site DeLand, Florida, United States, 32720 Less <<
NCT01080365 Healthy Phase 1 Completed - United States, Washington ... More >> Pfizer Investigational Site Tacoma, Washington, United States, 98418 Less <<
NCT02058277 Healthy Phase 1 Completed - United States, Florida ... More >> Pfizer Investigational Site DeLand, Florida, United States, 32720 Less <<
NCT00959946 - Terminated - -
NCT00959946 Advanced Breast Cancer (Parts ... More >>1 and 2) Advanced Pancreatic Cancer (Part 1) Advanced Colorectal Cancer (Part 1) Advanced Cholangiocarcinoma (Part 1) Advanced Glioblastoma Multiforme (Part 1) Less << Phase 1 Phase 2 Terminated - United States, Massachusetts ... More >> Pfizer Investigational Site Boston, Massachusetts, United States, 02114 United States, Michigan Pfizer Investigational Site Detroit, Michigan, United States, 84202 Australia, South Australia Pfizer Investigational Site Adelaide, South Australia, Australia, 5037 Belgium Pfizer Investigational Site Edegem, Belgium, 2650 France Pfizer Investigational Site Saint Herblain, France, 44805 Hong Kong Pfizer Investigational Site Hong Kong, Hong Kong Spain Pfizer Investigational Site Madrid, Spain, 28050 Less <<
NCT01374139 Philadelphia Chromosome Positi... More >>ve (Ph+) Chronic Myeloid Leukemia (CML) Less << Phase 1 Completed - Singapore ... More >> Pfizer Investigational Site Singapore, Singapore, 188770 Less <<
NCT02192294 Healthy Phase 1 Completed - United Kingdom ... More >> Quotient Clinical Ruddington Fields, Nottingham, United Kingdom, NG11 6JS Less <<
NCT00261846 Chronic Myeloid Leukemia PHASE2 COMPLETED 2015-08-06 City of Hope National Medical ... More >>Center, Duarte, California, 91010, United States|HealthONE Presbyterian, Denver, Colorado, 80218, United States|Rocky Mountain Cancer Centers, Denver, Colorado, 80218, United States|Georgetown University Hospital, Washington, D.C., District of Columbia, 20007, United States|Emory Clinic, Atlanta, Georgia, 30322, United States|Emory University Hospital, Atlanta, Georgia, 30322, United States|Winship Cancer Institute, Atlanta, Georgia, 30322, United States|Oncology Specialists, S.C., Niles, Illinois, 60714, United States|Indiana Blood and Marrow Transplantation, Indianapolis, Indiana, 46237, United States|LSU Health Sciences Center, Shreveport, Louisiana, 71103, United States|University Of Maryland Medical Center, Baltimore, Maryland, 21201, United States|University Of Maryland, Baltimore, Maryland, 21201, United States|Roswell Park Cancer Institute, Buffalo, New York, 14263, United States|Hudson Valley Hematology and Oncology Associates, Hawthorne, New York, 10532, United States|Westchester Oncology Hematology Group, P.C., Hawthorne, New York, 10532, United States|Westchester Oncology Hematology, Group, P.C., Hawthorne, New York, 10532, United States|New York Presbyterian Hospital, New York, New York, 10021, United States|New York Presbyterian Hospital, New York, New York, 10065, United States|University of Rochester Cancer Center Pharmacy, Rochester, New York, 14642, United States|University of Rochester Medical Center Strong Memorial Hospital - James P. Wilmot Cancer Center, Rochester, New York, 14642, United States|University of Rochester Medical Center, Rochester, New York, 14642, United States|University of Rochester-James P. Wilmot Cancer Center, Rochester, New York, 14642, United States|University of Rochester, Rochester, New York, 14642, United States|Westchester Medical Center, Valhalla, New York, 10595, United States|Penn State Milton S Hershey Medical Center, Hershey, Pennsylvania, 17033-0850, United States|MD Anderson Cancer Center, Houston, Texas, 77030-4009, United States|The University of Texas MD Anderson Cancer Center, Houston, Texas, 77030, United States|The University of Texas, Houston, Texas, 77030, United States|Virginia Commonwealth University, Richmond, Virginia, 23298-0157, United States|Hospital Italiano de la Plata, La Plata, Provincia de Buenos Aires, 1900, Argentina|Hospital Britanico, Buenos Aires, 1280, Argentina|Academia Nacional de Medicina-Instituto de Investigaciones Hematologicas, Buenos Aires, 1425, Argentina|Instituto Medico Especializado Alexander Fleming, Buenos Aires, 1426, Argentina|Clinica del Sol, Ciudad Autonoma de Buenos Aires, C1425DQI, Argentina|Centro Medico S.A., Corrientes, 3400, Argentina|Hospital Jose Ramon Vidal, Corrientes, 3400, Argentina|Hospital universitario austral, Pcia de Buenos Aires, B1629ODT, Argentina|Royal Adelaide Hospital, Adelaide, South Australia, 5000, Australia|Institute of Medical and Veterinary Science, Adelaide, SA 5000, Australia|Department of Clinical Haematology and Bone Marrow Transplantation, Melbourne, 3181, Australia|Royal Brisbane and Women's Hospital, Queensland, 4029, Australia|Haematology and Oncology Clinics of Australia, Queensland, 4101, Australia|Klinikum Kreuzschwestern Wels, Wels, 4600, Austria|Hospital Brigadeiro da Secretaria de Estado da Saude de Sao Paulo, Jardim Paulista, Sao Paulo/sp - Brazil, CEP: 01401-901, Brazil|Centro de Estudos da Disciplina dr Hematologia da Faculdade de Medicine do ABC, Santo Andre, Sp - Brazil, CEP 09060-650, Brazil|Hospital das Clinicas da Faculdade de Medicina da Universidade de Sao Paulo, Sao Paulo, Sp Brazil, 05403-000, Brazil|Hospital de Clinicas - Universidade Federal do Parana, Curitiba, PR, CEP: 80060-900, Brazil|Cross Cancer Institute, Edmonton, Alberta, T6G1Z2, Canada|BC Cancer Agency - Cancer Centre for the Southern Interior, Kelowna, British Columbia, V1Y 5L3, Canada|CancerCare Manitoba, Winnipeg, Manitoba, R3E 0V9, Canada|University Health Network Princess Margaret Hospital, Toronto, Ontario, M5G 2M9, Canada|Sir Mortimer B. Davis, Jewish General Hospital, Montreal, Quebec, H3T 1E2, Canada|Instituto Clinico Oncologico del Sur, Temuco, Chile|The First Hospital affiliated to the Medical School of Zhejiang University, Zhejiang, P.r China, 310003, China|Peking Union Medical College Hospital of Chinese Academy of Medical Sciences, Beijing, P.r. China, 100730, China|The Department of Hematology, The Chinese PLA General Hospital, Beijing, P.r. China, 100853, China|The Hematology Hospital of Chinese Academy of Medical Sciences, Tianjin, P.r. China, 300020, China|The Department of Hematology, Ruijin Hospital Affiliated to School of Medicine of Shanghai Jiaotong, Shanghai, 200025, China|Hospital Pablo Tobon Uribe, Medellin, Antioquia, 4459000, Colombia|Fundacion Santa Fe de Bogota, Bogota, Cundinamarca, Colombia|Biomedicum Helsinki, Helsinki, FIN-00029 HUS, Finland|Universitaet Mainz, Mainz, RP, 55101, Germany|University Hospital Carl Gustav Carus, Dresden, 01307, Germany|Universitaetsklinikum Hamburg - Eppendorf, Hamburg, 20246, Germany|Universitaetsklinikum Hamburg-Eppendorf, Hamburg, 20246, Germany|Universitaetsklinikum Magdeburg A. oe. R., Magdeburg, 39120, Germany|III Medizinische Klinik und Poliklinik, Mainz, 55101, Germany|Klinikum der Johann Gutenberg Universitaet Mainz, Mainz, 55131, Germany|Universitaet Mainz Iii. Medizinische Klinik Abteilung Fuer Haematologie, Mainz, D-55101, Germany|Universitaetsklinikum Mainz, Mainz, Germany|III. Medizinische Klinik, Mannheim, 68169, Germany|Pamela Youde Nethersole Eastern Hosp., Chai Wan, Hong Kong|Queen Mary Hospital, Hong Kong, Hong Kong|Fovarosi Onkormanyzat Egyesitett Szent Istvan es Szent Laszlo, Budapest, 1096, Hungary|Christian Medical College, Vellore, Tamil Nadu, 632 004, India|University of Bologna, Bologna, Province of Bologna, 40138, Italy|Azienda Ospedaliero - Universitaria San Luigi Gonzaga, Orbassano, Torino, 10043, Italy|AOU-S.Orsola-Malpighi - Universita degli Studi di Bologna, Bologna, 40138, Italy|Azienda Ospedaliera San Gerardo, Monza, 20900, Italy|The Catholic University of Korea, Seoul St. Mary Hospital, Seoul, 137-701, Korea, Republic of|Dept. of Hematology, Seoul, 138736, Korea, Republic of|Hospital Universitario "Dr. Jose Eleuterio Gonzalez", Nuevo Leon, 64460, Mexico|Centro Oncologico Estatal ISSEMYM, Toluca Estado de Mexico, CP50180, Mexico|VU University Medical Center, Amsterdam, 1081 HV, Netherlands|University Medical Center Groningen, Groningen, 9700 RB, Netherlands|UMCG - Pharmacy, Groningen, 9713 AP, Netherlands|Universitair Medisch Centrum Groningen, Groningen, 9713 GZ, Netherlands|VUMC, The Netherlands, Netherlands|Avd. for blodsykdommer, Trondheim, Norge, 7006, Norway|Hospital Nacional Edgardo Rebagliati Martins, Lima, 11, Peru|State Healthcare Institution, Sverdlovsk Regional Clinical Hospital, Ekaterinburg, 620102, Russian Federation|Kirov Research Institute of Hematology and Blood transfusion of Roszdrav Hematology clinic, Kirov, 610027, Russian Federation|Hematological Research Centre of RAMS, Moscow, 125167, Russian Federation|Moscow regional Clinical Research Institute named after M.F Vladimirsky, Moscow, 129110, Russian Federation|Rostov State Medical University of Roszdrav, Rostov-on Don, 344022, Russian Federation|Saint Petersburg State Medical University Hematology Department, Saint Petersburg, 197022, Russian Federation|Singapore General Hospital, Singapore, 169608, Singapore|University of the Free State, Bloemfontein, 9301, South Africa|University of Cape Town, Cape Town, 7925, South Africa|Johannesburg Hospital, Parktown, 2193, South Africa|Clinical Haematology Unit, Soweto, 2013, South Africa|Hospital Clinic de Barcelona (Hospital Clinic i Provincial), Barcelona, Catalonia, 08036, Spain|Hospital Universitari Clinic de Barcelona, Barcelona, Catalonia, 08036, Spain|Hospital Universitario La Princesa, Madrid, 28006, Spain|Hospital Clinico Universitario de Valencia (CHUV), Valencia, 46010, Spain|Akademiska University Hospital, Uppsala, 75185, Sweden|National Taiwan University Hospital - Section of Hematology-Oncology, Taipei 100, 10018, Taiwan|Northern Centre for Cancer Care - The Newcastle Upon Tyne Hospitals - NHS Foundation Trust, Newcastle Upon Tyne, North East England, NE7 7DN, United Kingdom|School of Clinical and Laboratory Sciences, University upon Tyne, North East England, NE1 7RU, United Kingdom|Hammersmith Hospital, London, W12 0HS, United Kingdom|Clinical Research Facility, Newcastle Upon Tyne, North East England, NE1 4LP, United Kingdom Less <<
NCT01025570 Pancreatic Cancer Phase 1 Terminated(Terminated due to s... More >>low accrual) Less << - United States, California ... More >> UCSF Helen Diller Family Comprehensive Cancer Center San Francisco, California, United States, 94115 United States, Utah Huntsman Cancer Institute, University of Utah Salt Lake City, Utah, United States, 84112 Less <<
NCT03106779 Chronic Myelogenous Leukemia Phase 3 Recruiting March 19, 2025 -
NCT00261846 Chronic Myeloid Leukemia PHASE2 COMPLETED 2015-08-06 City of Hope National Medical ... More >>Center, Duarte, California, 91010, United States|HealthONE Presbyterian, Denver, Colorado, 80218, United States|Rocky Mountain Cancer Centers, Denver, Colorado, 80218, United States|Georgetown University Hospital, Washington, D.C., District of Columbia, 20007, United States|Emory Clinic, Atlanta, Georgia, 30322, United States|Emory University Hospital, Atlanta, Georgia, 30322, United States|Winship Cancer Institute, Atlanta, Georgia, 30322, United States|Oncology Specialists, S.C., Niles, Illinois, 60714, United States|Indiana Blood and Marrow Transplantation, Indianapolis, Indiana, 46237, United States|LSU Health Sciences Center, Shreveport, Louisiana, 71103, United States|University Of Maryland Medical Center, Baltimore, Maryland, 21201, United States|University Of Maryland, Baltimore, Maryland, 21201, United States|Roswell Park Cancer Institute, Buffalo, New York, 14263, United States|Hudson Valley Hematology and Oncology Associates, Hawthorne, New York, 10532, United States|Westchester Oncology Hematology Group, P.C., Hawthorne, New York, 10532, United States|Westchester Oncology Hematology, Group, P.C., Hawthorne, New York, 10532, United States|New York Presbyterian Hospital, New York, New York, 10021, United States|New York Presbyterian Hospital, New York, New York, 10065, United States|University of Rochester Cancer Center Pharmacy, Rochester, New York, 14642, United States|University of Rochester Medical Center Strong Memorial Hospital - James P. Wilmot Cancer Center, Rochester, New York, 14642, United States|University of Rochester Medical Center, Rochester, New York, 14642, United States|University of Rochester-James P. Wilmot Cancer Center, Rochester, New York, 14642, United States|University of Rochester, Rochester, New York, 14642, United States|Westchester Medical Center, Valhalla, New York, 10595, United States|Penn State Milton S Hershey Medical Center, Hershey, Pennsylvania, 17033-0850, United States|MD Anderson Cancer Center, Houston, Texas, 77030-4009, United States|The University of Texas MD Anderson Cancer Center, Houston, Texas, 77030, United States|The University of Texas, Houston, Texas, 77030, United States|Virginia Commonwealth University, Richmond, Virginia, 23298-0157, United States|Hospital Italiano de la Plata, La Plata, Provincia de Buenos Aires, 1900, Argentina|Hospital Britanico, Buenos Aires, 1280, Argentina|Academia Nacional de Medicina-Instituto de Investigaciones Hematologicas, Buenos Aires, 1425, Argentina|Instituto Medico Especializado Alexander Fleming, Buenos Aires, 1426, Argentina|Clinica del Sol, Ciudad Autonoma de Buenos Aires, C1425DQI, Argentina|Centro Medico S.A., Corrientes, 3400, Argentina|Hospital Jose Ramon Vidal, Corrientes, 3400, Argentina|Hospital universitario austral, Pcia de Buenos Aires, B1629ODT, Argentina|Royal Adelaide Hospital, Adelaide, South Australia, 5000, Australia|Institute of Medical and Veterinary Science, Adelaide, SA 5000, Australia|Department of Clinical Haematology and Bone Marrow Transplantation, Melbourne, 3181, Australia|Royal Brisbane and Women's Hospital, Queensland, 4029, Australia|Haematology and Oncology Clinics of Australia, Queensland, 4101, Australia|Klinikum Kreuzschwestern Wels, Wels, 4600, Austria|Hospital Brigadeiro da Secretaria de Estado da Saude de Sao Paulo, Jardim Paulista, Sao Paulo/sp - Brazil, CEP: 01401-901, Brazil|Centro de Estudos da Disciplina dr Hematologia da Faculdade de Medicine do ABC, Santo Andre, Sp - Brazil, CEP 09060-650, Brazil|Hospital das Clinicas da Faculdade de Medicina da Universidade de Sao Paulo, Sao Paulo, Sp Brazil, 05403-000, Brazil|Hospital de Clinicas - Universidade Federal do Parana, Curitiba, PR, CEP: 80060-900, Brazil|Cross Cancer Institute, Edmonton, Alberta, T6G1Z2, Canada|BC Cancer Agency - Cancer Centre for the Southern Interior, Kelowna, British Columbia, V1Y 5L3, Canada|CancerCare Manitoba, Winnipeg, Manitoba, R3E 0V9, Canada|University Health Network Princess Margaret Hospital, Toronto, Ontario, M5G 2M9, Canada|Sir Mortimer B. Davis, Jewish General Hospital, Montreal, Quebec, H3T 1E2, Canada|Instituto Clinico Oncologico del Sur, Temuco, Chile|The First Hospital affiliated to the Medical School of Zhejiang University, Zhejiang, P.r China, 310003, China|Peking Union Medical College Hospital of Chinese Academy of Medical Sciences, Beijing, P.r. China, 100730, China|The Department of Hematology, The Chinese PLA General Hospital, Beijing, P.r. China, 100853, China|The Hematology Hospital of Chinese Academy of Medical Sciences, Tianjin, P.r. China, 300020, China|The Department of Hematology, Ruijin Hospital Affiliated to School of Medicine of Shanghai Jiaotong, Shanghai, 200025, China|Hospital Pablo Tobon Uribe, Medellin, Antioquia, 4459000, Colombia|Fundacion Santa Fe de Bogota, Bogota, Cundinamarca, Colombia|Biomedicum Helsinki, Helsinki, FIN-00029 HUS, Finland|Universitaet Mainz, Mainz, RP, 55101, Germany|University Hospital Carl Gustav Carus, Dresden, 01307, Germany|Universitaetsklinikum Hamburg - Eppendorf, Hamburg, 20246, Germany|Universitaetsklinikum Hamburg-Eppendorf, Hamburg, 20246, Germany|Universitaetsklinikum Magdeburg A. oe. R., Magdeburg, 39120, Germany|III Medizinische Klinik und Poliklinik, Mainz, 55101, Germany|Klinikum der Johann Gutenberg Universitaet Mainz, Mainz, 55131, Germany|Universitaet Mainz Iii. Medizinische Klinik Abteilung Fuer Haematologie, Mainz, D-55101, Germany|Universitaetsklinikum Mainz, Mainz, Germany|III. Medizinische Klinik, Mannheim, 68169, Germany|Pamela Youde Nethersole Eastern Hosp., Chai Wan, Hong Kong|Queen Mary Hospital, Hong Kong, Hong Kong|Fovarosi Onkormanyzat Egyesitett Szent Istvan es Szent Laszlo, Budapest, 1096, Hungary|Christian Medical College, Vellore, Tamil Nadu, 632 004, India|University of Bologna, Bologna, Province of Bologna, 40138, Italy|Azienda Ospedaliero - Universitaria San Luigi Gonzaga, Orbassano, Torino, 10043, Italy|AOU-S.Orsola-Malpighi - Universita degli Studi di Bologna, Bologna, 40138, Italy|Azienda Ospedaliera San Gerardo, Monza, 20900, Italy|The Catholic University of Korea, Seoul St. Mary Hospital, Seoul, 137-701, Korea, Republic of|Dept. of Hematology, Seoul, 138736, Korea, Republic of|Hospital Universitario "Dr. Jose Eleuterio Gonzalez", Nuevo Leon, 64460, Mexico|Centro Oncologico Estatal ISSEMYM, Toluca Estado de Mexico, CP50180, Mexico|VU University Medical Center, Amsterdam, 1081 HV, Netherlands|University Medical Center Groningen, Groningen, 9700 RB, Netherlands|UMCG - Pharmacy, Groningen, 9713 AP, Netherlands|Universitair Medisch Centrum Groningen, Groningen, 9713 GZ, Netherlands|VUMC, The Netherlands, Netherlands|Avd. for blodsykdommer, Trondheim, Norge, 7006, Norway|Hospital Nacional Edgardo Rebagliati Martins, Lima, 11, Peru|State Healthcare Institution, Sverdlovsk Regional Clinical Hospital, Ekaterinburg, 620102, Russian Federation|Kirov Research Institute of Hematology and Blood transfusion of Roszdrav Hematology clinic, Kirov, 610027, Russian Federation|Hematological Research Centre of RAMS, Moscow, 125167, Russian Federation|Moscow regional Clinical Research Institute named after M.F Vladimirsky, Moscow, 129110, Russian Federation|Rostov State Medical University of Roszdrav, Rostov-on Don, 344022, Russian Federation|Saint Petersburg State Medical University Hematology Department, Saint Petersburg, 197022, Russian Federation|Singapore General Hospital, Singapore, 169608, Singapore|University of the Free State, Bloemfontein, 9301, South Africa|University of Cape Town, Cape Town, 7925, South Africa|Johannesburg Hospital, Parktown, 2193, South Africa|Clinical Haematology Unit, Soweto, 2013, South Africa|Hospital Clinic de Barcelona (Hospital Clinic i Provincial), Barcelona, Catalonia, 08036, Spain|Hospital Universitari Clinic de Barcelona, Barcelona, Catalonia, 08036, Spain|Hospital Universitario La Princesa, Madrid, 28006, Spain|Hospital Clinico Universitario de Valencia (CHUV), Valencia, 46010, Spain|Akademiska University Hospital, Uppsala, 75185, Sweden|National Taiwan University Hospital - Section of Hematology-Oncology, Taipei 100, 10018, Taiwan|Northern Centre for Cancer Care - The Newcastle Upon Tyne Hospitals - NHS Foundation Trust, Newcastle Upon Tyne, North East England, NE7 7DN, United Kingdom|School of Clinical and Laboratory Sciences, University upon Tyne, North East England, NE1 7RU, United Kingdom|Hammersmith Hospital, London, W12 0HS, United Kingdom|Clinical Research Facility, Newcastle Upon Tyne, North East England, NE1 4LP, United Kingdom Less <<
NCT02130557 Leukemia, Myelogenous, Chronic... More >>, Breakpoint Cluster Region-Abelson Proto-oncogene (BCR-ABL) Positive Less << Phase 3 Active, not recruiting April 4, 2020 -
NCT02445742 Chronic Myeloblastic Leukaemia PHASE2 COMPLETED 2019-06-27 C. H. U. de Gran Canaria Dr. N... More >>egrín, Gran Canaria, Spain|C. H. Gregorio Mara?ón, Madrid, Spain|C. U. La Paz - H. U. La Paz, Madrid, Spain|H. Ramón y Cajal, Madrid, Spain|H. U. de la Princesa, Madrid, Spain|H. U. Fundación Jiménez Díaz, Madrid, Spain|Hospital Universitario 12 de Octubre, Madrid, Spain|C. H. Regional de Málaga , H. General, Málaga, Spain|H. U. Son Espases, Palma de Mallorca, Spain|C. Asistencial U. de Salamanca, Salamanca, Spain|C. H. U. de Santiago, Santiago de Compostela, Spain|H. Virgen de la Salud, Toledo, Spain|Clínica Quirón Zaragoza S.A., Zaragoza, Spain Less <<
NCT03205267 Chronic Myelogenous Leukaemia Phase 2 Recruiting October 2019 Germany ... More >> University Hospital Bonn Recruiting Bonn, Germany, 53127 Contact: Dominik Wolf, Prof. Dr.    +49 228 287 17233    dominik.wolf@ukb.uni-bonn.de Less <<
NCT02546375 Chronic Myeloid Leukaemia COMPLETED 2017-01-16 Royal Liverpool Hospital, Live... More >>rpool, Merseyside, L7 8XP, United Kingdom|Hammersmith Hospital, London, W12 0HS, United Kingdom|Nottingham University Hospital, Nottingham, NG5 1PB, United Kingdom Less <<
NCT01331291 Glioblastoma Phase 2 Completed - United States, Massachusetts ... More >> Massachusetts General Hospital Boston, Massachusetts, United States, 02114 Dana=Farber Cancer Institute Boston, Massachusetts, United States, 02115 Less <<
NCT01903733 Chronic Myeloid Leukemia Not Applicable Active, not recruiting April 3, 2020 -
NCT02782403 Leukemia Phase 1 Phase 2 Recruiting March 2021 United States, Texas ... More >> University of Texas MD Anderson Cancer Center Recruiting Houston, Texas, United States, 77030 Contact       pbose@mdanderson.org Less <<
NCT02130557 - Active, not recruiting - -
NCT02311998 Leukemia Phase 1 Phase 2 Recruiting April 2020 United States, Texas ... More >> University of Texas MD Anderson Cancer Center Recruiting Houston, Texas, United States, 77030 Less <<
NCT01331291 - Completed - -
NCT02810990 Chronic Myeloid Leukemia PHASE2 COMPLETED 2022-06-22 S.O.C. di Ematologia - Azienda... More >> Ospedaliera - SS. Antonio e Biagio e Cesare Arrigo, Alessandria, Italy|Azienda Ospedaliero - Universitaria Ospedali Riuniti Umberto I - G.M. LANCISI - G. SALESI, Ancona, Italy|UO Ematologia con trapianto-Università degli Studi di Bari Aldo Moro, Bari, Italy|Fausto Castagnetti, Bologna, Italy|Istituto di Ematologia "Lorenzo e A. Seragnoli" - Policlinico S. Orsola - Malpighi, Bologna, Italy|ASL N.8 - Ospedale "A. Businco" - Struttura Complessa di Ematologia e CTMO, Cagliari, Italy|Università di Catania - Cattedra di Ematologia - Ospedale "Ferrarotto", Catania, Italy|S.C. Ematologia ASO S. Croce e Carle, Cuneo, Italy|Arcispedale Sant'Anna Dipartimento di Scienze Mediche Sezione di Ematologia, Ferrara, Italy|Policlinico di Careggi, Firenze, Italy|Struttura Complessa di Ematologia Ospedali Riuniti Foggia, Foggia, Italy|IRCCS_AOU San Martino-IST-Ematologia 1-Monoblocco 11°piano- lato ponente, Genova, Italy|ASL Le/1 P.O. Vito Fazzi - U.O. di Ematologia ed UTIE, Lecce, Italy|Istituto Scientifico Romagnoli per lo Studio e la Cura dei Tumori- IRST, Meldola, Italy|Policlinico G. Martino Dipartimento di Medicina Interna - U.O. Messina, Messina, Italy|Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico UOC Oncoematologia, Milano, Italy|U.O. Ematologia e Trapianto di MIdollo - Ist.Scientifico Ospedale San Raffaele, Milano, Italy|Unità Trapianto di Midollo Ist. Nazionale Tumori, Milano, Italy|Azienda Ospedaliera "S.Gerardo", Monza, Italy|Azienda Università degli Studi di Napoli "Federico II" - Facoltà di Medicina e Chirurgia, Napoli, Italy|S.C.D.U. Ematologia - Università del Piemonte Orientale Amedeo Avogadro, Novara, Italy|Dip. di Scienze Cliniche e Biologiche - Ospedale S. Luigi Gonzaga-Medicina Interna 2, Orbassano, Italy|Università degli Studi di Padova - Ematologia ed Immunologia Clinica, Padova, Italy|U.O. di Ematologia con trapianto - A.U. Policlinico "Paolo Giaccone", Palermo, Italy|Cattedra di Ematologia CTMO Università degli Studi di Parma, Parma, Italy|S.C. Ematologia - Fondazione IRCCS Policlinico S. Matteo, Pavia, Italy|Dipartimento di Oncologia ed Ematologia - AUSL Ospedale G. da Saliceto, Piacenza, Italy|Ematologia - Ospedale San Carlo, Potenza, Italy|Dipartimento Oncologico - Ospedale S.Maria delle Croci, Ravenna, Italy|Unità Operativa Complessa di Ematologia - Arcispedale S. Maria Nuova, Reggio Emilia, Italy|Ospedale "Infermi", Rimini, Italy|U.O. di Ematologia - Centro Oncologico Basilicata, Rionero in Vulture, Italy|Complesso Ospedaliero S. Giovanni Addolorata, Roma, Italy|Divisione Ematologia - Università Campus Bio-Medico, Roma, Italy|Padiglione Cesalpino - I piano - Divisione di Ematologia - Ospedale S. Camillo, Roma, Italy|Università Cattolica del Sacro Cuore - Policlinico A. Gemelli, Roma, Italy|UOC Pronto Soccorso - Dipartimento Biotecnologie Cellulari Università di Roma "Sapienza", Roma, Italy|Istituto di Ematologia - IRCCS Ospedale Casa Sollievo della Sofferenza, San Giovanni Rotondo, Italy|U.O.C. Ematologia e Trapianti - A.O. Senese - Policlinico " Le Scotte", Siena, Italy|A.O. Santa Maria - Terni S.C Oncoematologia, Terni, Italy|Divisione di Ematologia - "Città della Salute e della Scienza di Torino", Torino, Italy|S.C. Ematologia 2 A.O. Città della Salute e della Scienza di Torino San Giovanni Battista, Torino, Italy|Clinica Ematologica-Centro Trapianti e Terapie cellulari, Udine, Italy|Medicina Interna I - Ospedale di Circolo, Varese, Italy|A. O. - Istituti Ospitalieri di Verona- Div. di Ematologia - Policlinico G.B. Rossi, Verona, Italy Less <<
NCT03023319 Carcinoma, Non-Small-Cell Lung... More >> Mesothelioma Bladder Cancer Ovarian Cancer Peritoneal Cancer Thymoma Thymus Cancer Uterine Cervical Cancer Less << Phase 1 Recruiting July 2020 United States, Ohio ... More >> UC Health Recruiting Cincinnati, Ohio, United States, 45219 Contact: UCCI Clinical Trials Office    513-584-7698    kastla@ucmail.uc.edu Less <<
NCT02546375 Chronic Myeloid Leukaemia COMPLETED 2017-01-16 Royal Liverpool Hospital, Live... More >>rpool, Merseyside, L7 8XP, United Kingdom|Hammersmith Hospital, London, W12 0HS, United Kingdom|Nottingham University Hospital, Nottingham, NG5 1PB, United Kingdom Less <<
NCT03128411 Leukemia, Chronic Myelogenous PHASE2 COMPLETED 2021-03-04 Fujita Health University Hospi... More >>tal, Toyoake-City, Aichi, 470-1192, Japan|Toyohashi Municipal Hospital, Toyohashi, Aichi, 441-8570, Japan|Akita University Hospital, Akita City, Akita, 010-8543, Japan|Japanese Red Cross Narita Hospital, Narita, Chiba, 286-8523, Japan|Ehime University Hospital, Toon-shi, Ehime, 791-0295, Japan|Kobe City Medical Center General Hospital, Kobe-city, Hyogo, 650-0047, Japan|Ishikawa Prefectural Central Hospital, Kanazawa, Ishikawa, 920-8530, Japan|Yokohama City University Medical Center, Yokohama, Kanagawa, 232-0024, Japan|National Hospital Organization Osaka Minami Medical Center, Kawachinagano, Osaka, 586-8521, Japan|Osaka City University Hospital, Osaka-City, Osaka, 545-8586, Japan|Kindai University Hospital, Osaka-Sayama, Osaka, 589-8511, Japan|Hamamatsu University Hospital, Hamamatsu, Shizuoka, 431-3192, Japan|Juntendo University Hospital, Bunkyo-ku, Tokyo, 113-8431, Japan|Tokyo Metropolitan Cancer and Infectious diseases Center Komagome Hospital, Bunkyo-ku, Tokyo, 113-8677, Japan|NTT Medical Center Tokyo, Shinagawa-ku, Tokyo, 141-8625, Japan|National Hospital Organization Disaster Medical Center, Tachikawa, Tokyo, 190-0014, Japan|Yamagata University Hospital, Yamagata-Shi, Yamagata, 990-9585, Japan|Chiba University Hospital, Chiba, 260-8677, Japan|National Hospital Organization Kyushu Cancer Center, Fukuoka, 811-1395, Japan|Saga University Hospital, Saga, 849-8501, Japan|Nippon Medical School Hospital, Tokyo, 113-8603, Japan Less <<
NCT02906696 Chronic Myelogenous Leukemia Phase 2 Recruiting October 2022 United States, Texas ... More >> University of Texas MD Anderson Cancer Center Recruiting Houston, Texas, United States, 77030 Less <<
NCT04258943 Philadelphia Chromosome Positi... More >>ve CML|Accelerated Phase Chronic Myelogenous Leukemia|Blastic Phase Chronic Myelogenous Leukemia|Chronic Phase Chronic Myelogenous Leukemia Less << PHASE1|PHASE2 ACTIVE_NOT_RECRUITING 2025-07-28 Children's Hospital of Alabama... More >>, Birmingham, Alabama, 35233, United States|Phoenix Childrens Hospital, Phoenix, Arizona, 85016, United States|Arkansas Children's Hospital, Little Rock, Arkansas, 72202-3591, United States|Kaiser Permanente Downey Medical Center, Downey, California, 90242, United States|Loma Linda University Medical Center, Loma Linda, California, 92354, United States|Kaiser Permanene-Oakland, Oakland, California, 94611, United States|Children's Hospital of Orange County, Orange, California, 92868, United States|Lucile Packard Children's Hospital Stanford University, Palo Alto, California, 94304, United States|Alfred I duPont Hospital for Children, Wilmington, Delaware, 19803, United States|Golisano Children's Hospital of Southwest Florida, Fort Myers, Florida, 33908, United States|University of Florida Health Science Center - Gainesville, Gainesville, Florida, 32610, United States|Nemours Children's Hospital, Orlando, Florida, 32827, United States|Kapiolani Medical Center for Women and Children, Honolulu, Hawaii, 96826, United States|Riley Hospital for Children, Indianapolis, Indiana, 46202, United States|Blank Children's Hospital, Des Moines, Iowa, 50309, United States|Norton Children's Hospital, Louisville, Kentucky, 40202, United States|Johns Hopkins University/Sidney Kimmel Cancer Center, Baltimore, Maryland, 21287, United States|Dana-Farber/Harvard Cancer Center, Boston, Massachusetts, 02215, United States|Children's Mercy Hospitals and Clinics, Kansas City, Missouri, 64108, United States|Children's Specialty Center of Nevada II, Las Vegas, Nevada, 89109, United States|Hackensack University Medical Center, Hackensack, New Jersey, 07601, United States|Morristown Medical Center, Morristown, New Jersey, 07960, United States|Rutgers Cancer Institute of New Jersey-Robert Wood Johnson University Hospital, New Brunswick, New Jersey, 08903, United States|Roswell Park Cancer Institute, Buffalo, New York, 14263, United States|The Steven and Alexandra Cohen Children's Medical Center of New York, New Hyde Park, New York, 11040, United States|Carolinas Medical Center/Levine Cancer Institute, Charlotte, North Carolina, 28203, United States|Children's Hospital Medical Center of Akron, Akron, Ohio, 44308, United States|Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, 45229, United States|Rainbow Babies and Childrens Hospital, Cleveland, Ohio, 44106, United States|Nationwide Children's Hospital, Columbus, Ohio, 43205, United States|Lehigh Valley Hospital-Cedar Crest, Bethlehem, Pennsylvania, 18017, United States|Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, 19104, United States|Children's Hospital of Pittsburgh of UPMC, Pittsburgh, Pennsylvania, 15224, United States|Rhode Island Hospital, Providence, Rhode Island, 02903, United States|East Tennessee Childrens Hospital, Knoxville, Tennessee, 37916, United States|Saint Jude Children's Research Hospital, Memphis, Tennessee, 38105, United States|Vanderbilt University/Ingram Cancer Center, Nashville, Tennessee, 37232, United States|Dell Children's Medical Center of Central Texas, Austin, Texas, 78723, United States|UT Southwestern/Simmons Cancer Center-Dallas, Dallas, Texas, 75390, United States|Baylor College of Medicine/Dan L Duncan Comprehensive Cancer Center, Houston, Texas, 77030, United States|M D Anderson Cancer Center, Houston, Texas, 77030, United States|Inova Fairfax Hospital, Falls Church, Virginia, 22042, United States|Children's Hospital of The King's Daughters, Norfolk, Virginia, 23507, United States|Seattle Children's Hospital, Seattle, Washington, 98105, United States|Children's Hospital of Wisconsin, Milwaukee, Wisconsin, 53226, United States Less <<
NCT05363488 Myeloid Leukemia COMPLETED 2021-10-08 eatson West of Scotland Cancer... More >> Centre, Glasgow, United Kingdom Less <<

Protocol

Bio Calculators
Preparing Stock Solutions 1mg 5mg 10mg

1 mM

5 mM

10 mM

1.89mL

0.38mL

0.19mL

9.43mL

1.89mL

0.94mL

18.85mL

3.77mL

1.89mL

References

 

Historical Records

Categories